Revue medicale suisseHumansBone Density Conservation AgentsOsteoporotic FracturesFibroblast Growth Factor-23Osteoporosis
[Metabolic bone diseases : what's new in 2025].
Ivan Padlina, Andrea Trombetti, Serge Ferrari, Emmanuel Biver
Published: 202610.53738/REVMED.2026.22.946.48208
Abstract
In 2025, osteoporosis management in Switzerland benefited from the introduction of abaloparatide, an anabolic PTHrP analogue that effectively reduces the risk of vertebral and non-vertebral fractures, with reimbursement criteria identical to those of…
Preview only. Read the full abstract at the source